Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Perinatal antiretroviral intensification to prevent intrapartum HIV transmission when antenatal antiretroviral therapy is initiated less than 8 weeks prior to delivery.

Lallemant M, Amzal B, Sripan P, Urien S, Cressey TR, Ngo-Giang-Huong N, Klinbuayaem V, Rawangban B, Sabsanong P, Siriwachirachai T, Jarupanich T, Kanjanavikai P, Wanasiri P, Koetsawang S, Jourdain G, Le Coeur S.

J Acquir Immune Defic Syndr. 2020 Mar 19. doi: 10.1097/QAI.0000000000002350. [Epub ahead of print]

PMID:
32205720
2.

Recommended First-Line Antiretroviral Therapy Regimens and Risk of Diabetes Mellitus in HIV-Infected Adults in Resource-Limited Settings.

Paengsai N, Jourdain G, Salvadori N, Tantraworasin A, Mary JY, Cressey TR, Chaiwarith R, Bowonwatanuwong C, Bhakeecheep S, Kosachunhanun N.

Open Forum Infect Dis. 2019 Sep 30;6(10):ofz298. doi: 10.1093/ofid/ofz298. eCollection 2019 Oct.

3.

Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings.

Gandhi M, Wang G, King R, Rodrigues WC, Vincent M, Glidden DV, Cressey TR, Bacchetti P, Spinelli MA, Okochi H, Siriprakaisil O, Klinbuayaem V, Mugo NR, Ngure K, Drain PK, Baeten JM.

AIDS. 2020 Feb 1;34(2):255-260. doi: 10.1097/QAD.0000000000002395.

PMID:
31634188
4.

Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list.

Penazzato M, Townsend CL, Rakhmanina N, Cheng Y, Archary M, Cressey TR, Kim MH, Musiime V, Turkova A, Ruel TD, Rabie H, Sugandhi N, Rojo P, Doherty M, Abrams EJ; PADO4 participants.

Lancet HIV. 2019 Sep;6(9):e623-e631. doi: 10.1016/S2352-3018(19)30193-6. Review.

PMID:
31498110
5.

Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network.

Li G, Bielicki JA, Ahmed ASMNU, Islam MS, Berezin EN, Gallacci CB, Guinsburg R, da Silva Figueiredo CE, Santarone Vieira R, Silva AR, Teixeira C, Turner P, Nhan L, Orrego J, Pérez PM, Qi L, Papaevangelou V, Triantafyllidou P, Iosifidis E, Roilides E, Sarafidis K, Jinka DR, Nayakanti RR, Kumar P, Gautam V, Prakash V, Seeralar A, Murki S, Kandraju H, Singh S, Kumar A, Lewis L, Pukayastha J, Nangia S, K N Y, Chaurasia S, Chellani H, Obaro S, Dramowski A, Bekker A, Whitelaw A, Thomas R, Velaphi SC, Ballot DE, Nana T, Reubenson G, Fredericks J, Anugulruengkitt S, Sirisub A, Wong P, Lochindarat S, Boonkasidecha S, Preedisripipat K, Cressey TR, Paopongsawan P, Lumbiganon P, Pongpanut D, Sukrakanchana PO, Musoke P, Olson L, Larsson M, Heath PT, Sharland M.

Arch Dis Child. 2020 Jan;105(1):26-31. doi: 10.1136/archdischild-2019-316816. Epub 2019 Aug 24.

6.

Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants.

Anugulruengkitt S, Suntarattiwong P, Ounchanum P, Srirompotong U, Jantarabenjakul W, Sophonphan J, Punnahitanon S, Pancharoen C, Cressey TR, Chokephaibulkit K, Puthanakit T; CIPHER_AEPEP study team.

Pediatr Infect Dis J. 2019 Oct;38(10):1045-1050. doi: 10.1097/INF.0000000000002426.

PMID:
31365477
7.

Urine Tenofovir Concentrations Correlate with Plasma and Relates to TDF Adherence: A Randomized Directly-observed Pharmacokinetic Trial (TARGET Study).

Drain PK, Kubiak RW, Siriprakaisil O, Klinbuayaem V, Quame-Amaglo J, Sukrakanchana PO, Tanasri S, Punyati P, Sirirungsi W, Cressey R, Bacchetti P, Okochi H, Baeten JM, Gandhi M, Cressey TR.

Clin Infect Dis. 2019 Jul 17. pii: ciz645. doi: 10.1093/cid/ciz645. [Epub ahead of print] Erratum in: Clin Infect Dis. 2019 Oct 15;69(9):1647.

PMID:
31314073
8.

Semi-quantification of HIV-1 protease inhibitor concentrations in clinical samples of HIV-infected patients using a gold nanoparticle-based immunochromatographic assay.

Thongkum W, Hadpech S, Tawon Y, Cressey TR, Tayapiwatana C.

Anal Chim Acta. 2019 Sep 13;1071:86-97. doi: 10.1016/j.aca.2019.04.060. Epub 2019 May 3.

PMID:
31128760
9.

Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected children.

Homkham N, Cressey TR, Bouazza N, Ingsrisawang L, Techakunakorn P, Mekmullica J, Borkird T, Puangsombat A, Na-Rajsima S, Treluyer JM, Urien S, Jourdain G.

PLoS One. 2019 May 16;14(5):e0216868. doi: 10.1371/journal.pone.0216868. eCollection 2019.

10.

Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV.

Waalewijn H, Turkova A, Rakhmanina N, Cressey TR, Penazzato M, Colbers A, Burger DM; Pediatric Antiretroviral Working Group (PAWG).

Ther Drug Monit. 2019 Aug;41(4):431-443. doi: 10.1097/FTD.0000000000000637. Review.

11.

Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus.

Salvadori N, Fan B, Teeyasoontranon W, Ngo-Giang-Huong N, Phanomcheong S, Luvira A, Puangsombat A, Suwannarat A, Srirompotong U, Putiyanun C, Cressey TR, Decker L, Khamduang W, Harrison L, Tierney C, Shepherd JA, Kourtis AP, Bulterys M, Siberry GK, Jourdain G.

Clin Infect Dis. 2019 Jun 18;69(1):144-146. doi: 10.1093/cid/ciy982.

PMID:
30924492
12.

Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling.

Schalkwijk S, Ter Heine R, Colbers A, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Moltó J, Mirochnick M, Karlsson MO, Burger DM.

J Antimicrob Chemother. 2019 May 1;74(5):1348-1356. doi: 10.1093/jac/dky567.

13.

Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test.

Gandhi M, Bacchetti P, Spinelli MA, Okochi H, Baeten JM, Siriprakaisil O, Klinbuayaem V, Rodrigues WC, Wang G, Vincent M, Cressey TR, Drain PK.

J Acquir Immune Defic Syndr. 2019 May 1;81(1):72-77. doi: 10.1097/QAI.0000000000001971.

PMID:
30664078
14.

Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus.

Cressey TR, Harrison L, Achalapong J, Kanjanavikai P, Patamasingh Na Ayudhaya O, Liampongsabuddhi P, Siriwachirachai T, Putiyanun C, Suriyachai P, Tierney C, Salvadori N, Chinwong D, Decker L, Tawon Y, Murphy TV, Ngo-Giang-Huong N, Siberry GK, Jourdain G; iTAP Study Team.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01686-18. doi: 10.1128/AAC.01686-18. Print 2018 Dec.

15.

Nevirapine Concentrations During the First Month of Life and Maternal Efavirenz Washout in High-Risk HIV-Exposed Infants Receiving Triple Antiretroviral Prophylaxis.

Anugulruengkitt S, Cressey TR, Suntarattiwong P, Ounchanum P, Srirompotong U, Jantarabenjakul W, Sophonphan J, Tawon Y, Punnahitanon S, Pancharoen C, Chokephaibulkit K, Puthanakit T; CIPHER_AEPEP Study Team.

Pediatr Infect Dis J. 2019 Feb;38(2):152-156. doi: 10.1097/INF.0000000000002195.

PMID:
30204660
16.

Incidence and clinical outcomes of diabetes mellitus in HIV-infected adults in Thailand: a retrospective cohort study.

Paengsai N, Jourdain G, Chaiwarith R, Tantraworasin A, Bowonwatanuwong C, Bhakeecheep S, Cressey TR, Mary JY, Salvadori N, Kosachunhanun N.

BMC Public Health. 2018 Aug 30;18(1):1079. doi: 10.1186/s12889-018-5967-7.

17.

Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV.

Ford D, Turner R, Turkova A, Penazzato M, Musiime V, Bwakura-Dangarembizi M, Violari A, Chabala C, Puthanakit T, Sudjaritruk T, Cressey TR, Lallemant M, Gibb DM.

J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 1:S40-S48. doi: 10.1097/QAI.0000000000001748.

18.

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial.

Turkova A, Moore CL, Butler K, Compagnucci A, Saïdi Y, Musiime V, Nanduudu A, Kaudha E, Cressey TR, Chalermpantmetagul S, Scott K, Harper L, Montero S, Riault Y, Bunupuradah T, Volokha A, Flynn PM, Bologna R, Ramos Amador JT, Welch SB, Nastouli E, Klein N, Giaquinto C, Ford D, Babiker A, Gibb DM; BREATHER (PENTA 16) trial Group.

PLoS One. 2018 Apr 23;13(4):e0196239. doi: 10.1371/journal.pone.0196239. eCollection 2018.

19.

A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women.

Schalkwijk S, Ter Heine R, Colbers AC, Huitema ADR, Denti P, Dooley KE, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Mirochnick M, Burger DM.

Clin Pharmacokinet. 2018 Nov;57(11):1421-1433. doi: 10.1007/s40262-018-0642-9.

20.

Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B.

Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C, Salvadori N, Cressey TR, Sirirungsi W, Achalapong J, Yuthavisuthi P, Kanjanavikai P, Na Ayudhaya OP, Siriwachirachai T, Prommas S, Sabsanong P, Limtrakul A, Varadisai S, Putiyanun C, Suriyachai P, Liampongsabuddhi P, Sangsawang S, Matanasarawut W, Buranabanjasatean S, Puernngooluerm P, Bowonwatanuwong C, Puthanakit T, Klinbuayaem V, Thongsawat S, Thanprasertsuk S, Siberry GK, Watts DH, Chakhtoura N, Murphy TV, Nelson NP, Chung RT, Pol S, Chotivanich N.

N Engl J Med. 2018 Mar 8;378(10):911-923. doi: 10.1056/NEJMoa1708131.

21.

A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines.

Pinto JA, Capparelli EV, Warshaw M, Zimmer B, Cressey TR, Spector SA, Qin M, Smith B, Siberry GK, Mirochnick M; IMPAACT P1083 Team.

Pediatr Infect Dis J. 2018 Feb;37(2):e29-e35. doi: 10.1097/INF.0000000000001817.

22.

Brief Report: AIDS-Defining Events and Deaths in HIV-Infected Children and Adolescents on Antiretrovirals: A 14-Year Study in Thailand.

Traisathit P, Delory T, Ngo-Giang-Huong N, Somsamai R, Techakunakorn P, Theansavettrakul S, Kanjanavanit S, Mekmullica J, Ngampiyaskul C, Na-Rajsima S, Lallemant M, Cressey TR, Jourdain G, Collins IJ, Le Coeur S.

J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):17-22. doi: 10.1097/QAI.0000000000001571.

23.

Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations.

Clarke DF, Penazzato M, Capparelli E, Cressey TR, Siberry G, Sugandhi N, Mirochnick M; WHO Paediatric Antiretroviral Working Group.

Expert Rev Clin Pharmacol. 2018 Jan;11(1):83-93. doi: 10.1080/17512433.2018.1393331. Epub 2017 Nov 8. Review.

PMID:
29039686
24.

Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents.

Jantarabenjakul W, Anugulruengkitt S, Kasipong N, Thammajaruk N, Sophonphan J, Bunupuradah T, Cressey TR, Colbers A, Burger DM, Phongsamart W, Puthanakit T, Pancharoen C; HIVNAT 220 study.

Antivir Ther. 2018;23(3):259-265. doi: 10.3851/IMP3198.

PMID:
28994660
25.

A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.

Cressey TR, Siriprakaisil O, Klinbuayaem V, Quame-Amaglo J, Kubiak RW, Sukrakanchana PO, Than-In-At K, Baeten J, Sirirungsi W, Cressey R, Drain PK.

BMC Infect Dis. 2017 Jul 14;17(1):496. doi: 10.1186/s12879-017-2593-4.

26.

Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates.

Cressey TR, Punyawudho B, Le Coeur S, Jourdain G, Saenjum C, Capparelli EV, Jittayanun K, Phanomcheong S, Luvira A, Borkird T, Puangsombat A, Aarons L, Sukrakanchana PO, Urien S, Lallemant M; PHPT-5 study team.

J Acquir Immune Defic Syndr. 2017 Aug 15;75(5):554-560. doi: 10.1097/QAI.0000000000001447.

27.

Incidence of Tuberculosis and Associated Mortality in a Cohort of Human Immunodeficiency Virus-Infected Children Initiating Antiretroviral Therapy.

Salvadori N, Ngo-Giang-Huong N, Duclercq C, Kanjanavanit S, Ngampiyaskul C, Techakunakorn P, Puangsombat A, Figoni J, Mary JY, Collins IJ, Cressey TR, Le Cœur S, Sirirungsi W, Lallemant M, McIntosh K, Jourdain G.

J Pediatric Infect Dis Soc. 2017 Jun 1;6(2):161-167. doi: 10.1093/jpids/piw090.

28.

Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients.

Bouazza N, Cressey TR, Foissac F, Bienczak A, Denti P, McIlleron H, Burger D, Penazzato M, Lallemant M, Capparelli EV, Treluyer JM, Urien S.

J Antimicrob Chemother. 2017 Feb;72(2):490-495. doi: 10.1093/jac/dkw444. Epub 2016 Oct 24.

PMID:
27798221
29.

Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults.

Cressey TR, Hazra R, Wiznia A, Foca M, Jean-Philippe P, Graham B, King JR, Britto P, Carey VJ, Acosta EP, Yogev R; IMPAACT P1058A Team.

Pediatr Infect Dis J. 2016 Dec;35(12):1333-1335.

30.

Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen.

Jourdain G, Ngo-Giang-Huong N, Cressey TR, Hua L, Harrison L, Tierney C, Salvadori N, Decker L, Traisathit P, Sirirungsi W, Khamduang W, Bowonwatanuwong C, Puthanakit T, Siberry GK, Watts DH, Murphy TV, Achalapong J, Hongsiriwon S, Klinbuayaem V, Thongsawat S, Chung RT, Pol S, Chotivanich N.

BMC Infect Dis. 2016 Aug 9;16:393. doi: 10.1186/s12879-016-1734-5.

31.

Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.

Larson KB, Cressey TR, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Gonzalez A, Britto P, Carey VJ, Acosta EP; International Maternal Pediatric and Adolescent AIDS Clinical Trial Protocol P1058A Team.

J Pediatric Infect Dis Soc. 2016 Jun;5(2):131-7. doi: 10.1093/jpids/piu142. Epub 2015 Jan 28.

32.

Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.

Foca M, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Britto P, Carey VJ, King J, Acosta EP, Cressey TR; IMPAACT P1058A Team.

Pediatr Infect Dis J. 2016 Sep;35(9):e271-4. doi: 10.1097/INF.0000000000001214.

33.

Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.

Cressey TR, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Gonzalez A, Britto P, Carey VJ, Fletcher CV, Acosta EP; IMPAACT P1058A Team.

J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):294-296. doi: 10.1093/jpids/piw017.

34.

Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.

Tran AH, Best BM, Stek A, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, George K, Cressey TR, Chakhtoura N, Smith E, Shapiro DE, Mirochnick M; IMPAACT P1026s Protocol Team.

J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):289-96. doi: 10.1097/QAI.0000000000000968.

35.

A Population Pharmacokinetic/Pharmacodynamic Model Predicts Favorable HDL Cholesterol Changes Over the First 5 Years in Children Treated With Current Efavirenz-Based Regimens.

Homkham N, Cressey TR, Ingsrisawang L, Bouazza N, Ngampiyaskul C, Hongsiriwon S, Srirojana S, Kanjanavanit S, Bhakeecheep S, Coeur SL, Salvadori N, Treluyer JM, Jourdain G, Urien S.

J Clin Pharmacol. 2016 Sep;56(9):1076-83. doi: 10.1002/jcph.701. Epub 2016 Feb 24.

PMID:
26749102
36.

Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.

Sripan P, Le Coeur S, Ingsrisawang L, Cressey TR, Bouazza N, Foissac F, Ngo-Giang-Huong N, Traisathit P, Srirompotong U, Ayudhaya OP, Puangsombat A, Jungpipun J, Jittayanun K, Tréluyer JM, Jourdain G, Lallemant M, Urien S.

Antivir Ther. 2016;21(5):435-40. doi: 10.3851/IMP3001. Epub 2015 Oct 22.

37.

Expedient screening for HIV-1 protease inhibitors using a simplified immunochromatographic assay.

Kitidee K, Khamaikawin W, Thongkum W, Tawon Y, Cressey TR, Jevprasesphant R, Kasinrerk W, Tayapiwatana C.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 May 15;1021:153-158. doi: 10.1016/j.jchromb.2015.10.003. Epub 2015 Oct 17.

PMID:
26490422
38.

Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults.

Rattanapunya S, Cressey TR, Rueangweerayut R, Tawon Y, Kongjam P, Na-Bangchang K.

Malar J. 2015 Oct 9;14:400. doi: 10.1186/s12936-015-0916-8.

39.

Pharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai Adults.

Rattanapunya S, Cressey TR, Rueangweerayut R, Tawon Y, Kongjam P, Na-Bangchang K.

Am J Trop Med Hyg. 2015 Dec;93(6):1383-90. doi: 10.4269/ajtmh.15-0453. Epub 2015 Sep 28.

40.

Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand.

Lallemant M, Le Coeur S, Sirirungsi W, Cressey TR, Ngo-Giang-Huong N, Traisathit P, Klinbuayaem V, Sabsanong P, Kanjanavikai P, Jourdain G, Mcintosh K, Koetsawang S; PHPT-5 study investigators.

AIDS. 2015 Nov 28;29(18):2497-507. doi: 10.1097/QAD.0000000000000865.

41.

Correction: Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV.

Sripan P, Le Coeur S, Amzal B, Ingsrisawang L, Traisathit P, Ngo-Giang-Huong N, McIntosh K, Cressey TR, Sangsawang S, Rawangban B, Kanjanavikai P, Tréluyer JM, Jourdain G, Lallemant M, Urien S.

PLoS One. 2015 Aug 28;10(8):e0137368. doi: 10.1371/journal.pone.0137368. eCollection 2015. No abstract available.

42.

Efavirenz Concentrations and Probability of HIV Replication in Children.

Homkham N, Cressey TR, Bouazza N, Chanta C, Aurpibul L, Narkbunnam T, Krikajornkitti S, Kamonpakorn N, Lallemant M, Ingsrisawang L, Salvadori N, Treluyer JM, Urien S, Jourdain G.

Pediatr Infect Dis J. 2015 Nov;34(11):1214-7. doi: 10.1097/INF.0000000000000854.

PMID:
26226442
43.

Correction: Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV.

Sripan P, Le Coeur S, Amzal B, Ingsrisawang L, Traisathit P, Ngo-Giang-Huong N, McIntosh K, Cressey TR, Sangsawang S, Rawangban B, Kanjanavikai P, Tréluyer JM, Jourdain G, Lallemant M, Urien S.

PLoS One. 2015 Jun 26;10(6):e0130917. doi: 10.1371/journal.pone.0130917. eCollection 2015. No abstract available.

44.

Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV.

Sripan P, Le Coeur S, Amzal B, Ingsrisawang L, Traisathit P, Ngo-Giang-Huong N, McIntosh K, Cressey TR, Sangsawang S, Rawangban B, Kanjanavikai P, Tréluyer JM, Jourdain G, Lallemant M, Urien S.

PLoS One. 2015 May 19;10(5):e0126647. doi: 10.1371/journal.pone.0126647. eCollection 2015. Erratum in: PLoS One. 2015;10(6):e0130917. PLoS One. 2015;10(8):e0137368.

45.

Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.

Stek A, Best BM, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, Cressey TR, Mofenson LM, Smith E, Shapiro D, Mirochnick M.

J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):33-41. doi: 10.1097/QAI.0000000000000668.

46.

Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.

Cressey TR, Avihingsanon A, Halue G, Leenasirimakul P, Sukrakanchana PO, Tawon Y, Jaisieng N, Jourdain G, Podany AT, Fletcher CV, Klinbuayaem V, Bowonwatanuwong C.

Clin Infect Dis. 2015 Aug 15;61(4):633-9. doi: 10.1093/cid/civ346. Epub 2015 Apr 28.

47.

New-Onset Diabetes and Antiretroviral Treatments in HIV-Infected Adults in Thailand.

Riyaten P, Salvadori N, Traisathit P, Ngo-Giang-Huong N, Cressey TR, Leenasirimakul P, Techapornroong M, Bowonwatanuwong C, Kantipong P, Nilmanat A, Yutthakasemsunt N, Chutanunta A, Thongpaen S, Klinbuayaem V, Decker L, Le Cœur S, Lallemant M, Capeau J, Mary JY, Jourdain G.

J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):453-9. doi: 10.1097/QAI.0000000000000647.

PMID:
25886928
48.

Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy.

Suaysod R, Ngo-Giang-Huong N, Salvadori N, Cressey TR, Kanjanavanit S, Techakunakorn P, Krikajornkitti S, Srirojana S, Laomanit L, Chalermpantmetagul S, Lallemant M, Le Cœur S, McIntosh K, Traisathit P, Jourdain G.

Clin Infect Dis. 2015 Jul 1;61(1):95-101. doi: 10.1093/cid/civ271. Epub 2015 Apr 1.

PMID:
25838288
49.

Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.

Aurpibul L, Cressey TR, Sricharoenchai S, Wittawatmongkol O, Sirisanthana V, Phongsamart W, Sudjaritruk T, Chokephaibulkit K.

Pediatr Infect Dis J. 2015 Apr;34(4):392-7. doi: 10.1097/INF.0000000000000633. Erratum in: Pediatr Infect Dis J. 2015 Aug;34(8):847.

PMID:
25760566
50.

No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults.

Sirirungsi W, Urien S, Harrison L, Kamkon J, Tawon Y, Luekamlung N, Thongpaen S, Nilmanat A, Jourdain G, Lallemant M, Le Coeur S, Ngo-Giang-Huong N, Owen A, Cressey TR.

J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):e56-9. doi: 10.1097/QAI.0000000000000504. No abstract available.

Supplemental Content

Loading ...
Support Center